Mirum Completes Enrollment & Screening in Liver Disease Studies

Core Insights - Mirum Pharmaceuticals has completed enrollment in the phase III AZURE-1 study and screening in the AZURE-4 study for its candidate brelovitug, targeting chronic hepatitis delta virus (HDV) [1][5] - The company anticipates reporting top-line 24-week data from both studies in the second half of 2026, which will support a biologics license application (BLA) submission in 2027 [2][5] - Following the announcement, Mirum's shares fell by 5.6%, although the stock has increased by 11.2% year-to-date, outperforming the industry average of 8.1% [2] Study and Drug Development - The AZURE-1 and AZURE-4 studies are assessing a composite endpoint of virologic response and ALT normalization at 24 weeks, aligning with FDA guidelines for accelerated approval [6] - Brelovitug, a fully human monoclonal antibody, was added to Mirum's pipeline through the acquisition of Bluejay Therapeutics in January 2026, enhancing the company's focus on severe liver diseases [3] Financial Performance - Mirum's lead product, Livmarli, generated net sales of $360 million in 2025, reflecting a year-over-year increase of 68.8%, and is a significant revenue driver for the company [8] - Sales of bile acid products, including Livmarli, increased by 31% year-over-year to $161.3 million in 2025 [8] Market Position - Mirum currently holds a Zacks Rank of 3 (Hold), with other biotech stocks like ANI Pharmaceuticals, ALX Oncology, and Replimune Group rated higher [9]